Arixtra (Fondaparinux) Level
Reference Values Describes reference intervals and additional information for interpretation of test results. May include intervals based on age and sex when appropriate. Intervals are Mayo-derived, unless otherwise designated. If an interpretive report is provided, the reference value field will state this.
Interpretive comments: Dosing protocols for Arixtra (fondaparinux) have been validated by empiric clinical trials. The relationship between pharmacokinetic parameters and either efficacy or safety (bleeding) is not well defined. Peak levels are generally drawn 3-4 hours after drug administration. Fondaparinux plasma concentrations have been reported to range from 0.1 to 0.5 mg/L for adult patients on thromboprophylaxis and from 0.6 to 1.5 mg/L for adults on therapeutic doses (Depasse F, et al, J Thromb Haemost 2004; 2:346-8). A therapeutic level of 0.5-1.0 mg/L has been suggested in a pediatric study (Young G, et al. Pediatric Blood Cancer 2011; 57:1049-54).